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Abstract Renal transplantation (Tx) is the treatment of
choice for end-stage renal disease. The incidence of acute
rejection after renal Tx has decreased because of improving
early immunosuppression, but the risk of disease recurrence
(DR) is becoming relatively high, with a greater prevalence
in children than in adults, thereby increasing patient
morbidity, graft loss (GL) and, sometimes, mortality rate.
The current overall graft loss to DR is 7–8%, mainly due to
primary glomerulonephritis (70–80%) and inherited meta-
bolic diseases. The more typical presentation is a recurrence
of the full disease, either with a high risk of GL (focal and
segmental glomerulosclerosis 14–50% DR, 40–60%
GL; atypical haemolytic uraemic syndrome 20–80% DR,
10–83% GL; membranoproliferative glomerulonephritis
30–100% DR, 17–61% GL; membranous nephropathy
∼30% DR, ∼50% GL; lipoprotein glomerulopathy ∼100%
DR and GL; primary hyperoxaluria type 1 80–100% DR
and GL) or with a low risk of GL [immunoglobulin (Ig)A
nephropathy 36–60% DR, 7–10% GL; systemic lupus
erythematosus 0–30% DR, 0–5% GL; anti-neutrophilic
cytoplasmic antibody (ANCA)-associated glomerulo-
nephritis]. Recurrence may also occur with a delayed risk
of GL, such as insulin-dependent diabetes mellitus, sickle
cell disease, endemic nephropathy, and sarcoidosis. In other
primary diseases, the post-Tx course may be complicated
by specific events that are different from overt recurrence:
proteinuria or cancer in some genetic forms of nephrotic
syndrome, anti-glomerular basement membrane antibodies-
associated glomerulonephritis (Alport syndrome, Good-
pasture syndrome), and graft involvement as a consequence
of lower urinary tract abnormality or human immunodefi-
ciency virus (HIV) nephropathy. Some other post-Tx
conditions may mimic recurrence, such as de novo
membranous glomerulonephritis, IgA nephropathy, micro-
angiopathy, or isolated specific deposits (cystinosis, Fabry
disease). Adequate strategies should therefore be added to
kidney Tx, such as donor selection, associated liver Tx,
plasmatherapy, specific immunosuppression protocols. In
such conditions, very few patients may be excluded from
kidney Tx only because of a major risk of DR and repeated
GL. In the near future the issue of DR after kidney Tx may
benefit from alternatives to organ Tx, such as recombinant
proteins, specific monoclonal antibodies, cell/gene therapy,
and chaperone molecules.
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Introduction
Renal transplantation (Tx) is the treatment of choice for stage 5
chronic kidney disease (CKD) and end-stage renal disease
(ESRD). The risk of disease recurrence following renal Tx is
becoming relatively high, due to increased immunosuppres-
sion and reduced acute rejection. Disease recurrence has a
greater prevalence in children than in adults, thereby increasing
patient morbidity, graft loss and, sometimes, mortality rates.
Indeed, the current overall graft loss to acute rejection in
children is 8–9% vs 7–8% to disease recurrence, mainly due to
primary glomerulonephritis (70–80%) and inherited metabolic
diseases (Table 1) [1–11]. Relative risk for graft failure in
those with recurrent and de novo disease is 1.9 times that for
the population in whom disease did not reoccur [3]. Changes
in immunosuppression protocols that occurred during the past
decades have not significantly modified the incidence of
recurring diseases after Tx [3, 12].
The spectrum of recurrence is rather wide and mainly
depends on the primary disease itself, ranging from the
recurrence of the full disease—with various risks of graft
loss—to the recurrence of specific features of the disease. In
addition, some renal complications after transplantation may
mimic recurrence but are based on different issues.
Unfortunately, there is limited evidence on the management
of post-Tx disease recurrence, and clinical practice is usually
based on non-randomized and uncontrolled case series.
Recurrence of the ‘full’ disease
Recurrence with a high risk of graft loss
Nephrotic syndrome
Epidemiology
Of children with nephrotic syndrome (NS), 10–15% do not
respond to corticosteroids and, among children with ESRD,
10–15% of them first present with the NS, i.e. the most
common cause for renal Tx among acquired kidney
diseases. Most of them show idiopathic focal and segmental
glomerulosclerosis (FSGS) on renal biopsy examination,
the yearly incidence of which seems to be increasing. The
risk of recurrence in a first graft is 14–50%, with a risk of
graft loss of 40–60%; in other words, the relative risk for
graft failure from FSGS after Tx is 2.25 compared to
non-recurrent diseases [1, 3, 4]. The risk of recurrence in a
second graft after a first graft loss to recurrence is
60–100%. Some risk factors have been reported, as shown
in Table 2. However, current knowledge on the pathophys-
iology of NS suggests that it may be either an immunolog-
ical disease or a genetic disease, with a common
histological pattern, i.e. FSGS, but has a different risk of
recurrence (Table 3).
In some rare patients with the so-called ‘IgM nephrop-
athy’ the disease has recurred after Tx, so that such form of
steroid-resistant NS may be regarded as a distinct disease
entity [15].
Pathophysiology
The risk of recurrence mainly affects patients with primary
idiopathic FSGS involving T-cell dysfunction and a
putative circulating factor which may be bound to immu-
noglobulin. Several candidate agents have been proposed,
such as cytokine, lymphokine, growth factor, and comple-
ment [16]. All of them may have the same endpoint, i.e. the
glomerular epithelial cell.
Genetics
Genetic underlying diseases have been described in FSGS.
Recently, genes involved in the structure and function of
the glomerular podocyte have been identified [17, 18]. The
role of these genetic defects in the development of FSGS is
still incompletely understood. However, in a recent series of
83 patients, those with a disease causing podocin mutation
had no recurrence after renal Tx, whereas the risk of
recurrence was over 50% in patients without mutation [19].
Primary disease Recurrence rate Graft loss to recurrence
FSGS 14–50% 40–60%
Atypical HUS 20–80% 10–83%
Typical HUS 0–1% 0–1%
MPGN type 1 30–77% 17–50%
MPGN type 2 66–100% 25–61%
SLE nephritis 0–30% 0–5%
IgA nephritis (Berger disease) 35–60% 7–10%
Henoch–Schönlein nephritis 31–100% 8–22%
Primary hyperoxaluria type 1 90–100% 80–100%
Table 1 Recurrence of primary
disease after the first renal
transplantation [1–11]
(FSGS focal segmental
glomerulosclerosis, HUS
haemolytic uraemic syndrome,
IgA immunoglobulin A,
MPGN membranoproliferative
glomerulonephritis, SLE
systemic lupus
erythematosus)
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Presentation
The recurrence of NS after Tx is based on FSGS as a
primary disease, resulting in ESRD, presence of post-Tx
nephrotic range proteinuria, with or without proven FSGS
in the graft. The presentation of recurrence includes early
massive proteinuria (78% during the first month after Tx,
often as early as in the first urine from the graft) and
sometimes graft failure and arterial hypertension [13].
There may be a delay in initial presentation coincident
with acute tubular necrosis which occurs more frequently in
renal Tx for FSGS. The onset of FSGS lesions is a
secondary phenomenon which can occur early following
recurrence of proteinuria.
Prognosis
The prognosis of untreated recurrent NS is poor, and there
is no current evidence of any kind of treatment. However, it
is not ethical to keep the patient on dialysis, so that some
therapeutic options have been advocated and include active
treatments, preventive measures and rescue treatments [14].
Global approach to transplantation
Some general measures are currently available: (1) an exact
diagnosis is required in any patient; (2) DNA should be
analysed/stored according to local convenience; (3) in
patients with persistent NS, pre-emptive Tx may be
dangerous because of the presence of heavy proteinuria
from native kidneys, with the risk of both graft thrombosis
and delayed diagnosis of recurrence; (4) pre-Tx bilateral
nephrectomy is therefore recommended, with the patient on
dialysis for a limited period of time. In addition, pre-Tx
native nephrectomy may reduce the risk of recurrence per
se; a reduction of the antigenic load that stimulates the
putative permeability factor has been advocated [20].
Interestingly, the transplanted kidney provides a unique
environment, since immunosuppressive agents [e.g.
cyclosporine A (CsA)] that have not been successful on
native kidneys may be effective in preventing post-Tx
recurrence. Indeed, there is transient or no efficacy of such
drugs on native kidneys because of their late use in the
presence of advanced glomerular damage, whereas there is
a potential benefit of early immunological intervention
Primary idiopathic SRNS Inherited SRNS
A multifactorial disease A renal disease
T-cell dysregulation Abnormal podocyte–GBM complex
Podocyte as a target Podocyte as a disease
Idiopathic FSGS Genetic forms of NS Syndromic forms of NS
Finnish type NS (NPHS1) WT1-associated SRNS
Other recessive FSGS Pierson Sd, Schimke Sd
(NPHS2, NPHS3) Charcot–Marie–Tooth SRNS
Dominant FSGS
(ACTN4, TRPC6, CD2AP)
Circulating factor No circulating factor
Immunosuppression available No effect of immunosuppression
Table 3 Two groups of steroid-
resistant nephrotic syndromes
(SRNS) leading to end-stage
renal disease in children (GBM
glomerular basement membrane,
Sd syndrome)
Table 2 Risk factors for recurrence of the nephrotic syndrome [1, 13, 14] (HLA human leukocyte antigen)
Proven increased risk Independent/controversial risk factors Proven decreased risk
Recurrence in a first graft Gender African–American recipients
Onset of NS during childhood Mesangial hypercellularity Genetic and syndromic NS
White and Asian recipients Age at onset over 6 years
Rapid course to ESRD (< 3 years) Presence of FSGS circulating factor
Donor source
HLA typing/matching
Time interval on dialysis prior to Tx
Type of immunosuppressive therapy
Use of induction therapy
Bilateral nephrectomy of native kidneys
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prior to Tx regarding the onset of glomerular damage in the
graft.
In the absence of preventive measures, including pre-
treatment of the recipient with CsA (with or without
plasmapheresis), living donors should be avoided, since the
relative risk of graft failure is 1.75 compared with that when
kidneys from living donors are used in non-FSGS recipients
[21]. This suggests a potential role for unknown genetic
parameters that may trigger the development of FSGS.
Experimental data
In rats CsA has been shown to prevent the increase in
glomerular permeability caused by serum from patients
with FSGS. On the other hand, other experiments in animal
models have shown that glomerular permeability may
be prevented by components of high-density lipoproteins,
purified components of Tripterygium wilfordii, and
20-hydroxyeicosa-tetra-enoic acid (20-HETE).
Active treatment of overt recurrence
Plasmapheresis using 4–5% albumin restitution (approxi-
mately ten sessions within 2 weeks, then weekly sessions
for a total of 2 months, then adapted to individual response)
has been successful in many patients. The use of more
sophisticated methods, such as adsorption onto protein A
columns or tryptophan immuno-adsorption, has no superior
benefit [22]. Plasmapheresis has been used with or without
cyclophosphamide instead of mycophenolate/azathioprine
for an average of 12 weeks, on the basis of its long-lasting
effect on T-cells [23]. Approximately 60% of patients attain
complete remission, and the success rate is higher with
early plasmapheresis, i.e. starting during the first 3–4 days
after Tx. The adjunction of immunoglobulin replacement
does not seem to have any benefit.
Controlled and randomized studies in children with
primary SRNS have shown that CsA is effective in
inducing remission. CsA may influence direct immunolog-
ical phenomena and/or inhibit the effect of glomerular
permeability factor; it may also act through vasoconstric-
tion. High doses of CsA (either orally at a dose of
13–35 mg/kg per day, or with continuous infusion at a
dose of 3 mg/kg per day in order to avoid nephrotoxic peak
levels; blood concentration between 200 ng/ml and 350 ng/
ml) for 1–3 weeks have given stimulating results in a
significant number of patients [24, 25]. The rationale
behind maintaining high CsA blood concentration is to
overcome the effect of high serum levels of low-density
lipoprotein (LDL) (secondary to recurrent NS), which binds
CsA and is further responsible for low levels of free
available CsA. However, some patients have required
further plasmapheresis, and others have experienced CsA
nephrotoxicity. In the long term, approximately 60% of the
patients are in complete remission. The use of CsA as a
first-step treatment may limit the efficacy of plasmaphere-
sis, which may, therefore, be postponed.
The benefit of another anti-calcineurin agent, i.e.
tacrolimus, on native kidney NS is scarce and has not been
demonstrated in post-Tx recurrent NS so far; some patients
experiencing a successful post-Tx strategy using CsA have
experienced a late recurrence when switched from CsA to
tacrolimus [14].
Antibody induction therapy using either anti-lymphocyte
globulin or anti-interleukin (IL)2R antibodies (basiliximab,
daclizumab) has given conflicting results, so that they are
no longer used in such patients [24]. Recently rituximab, a
chimeric monoclonal antibody that acts by inhibiting
CD20-mediated B-cell proliferation and differentiation,
has been used in some patients with recurrent NS under
various conditions [timing of the first dose, associated
post-transplantation lymphoproliferative disorder (PTLD)]
[26]. Paediatric patients were given 375 mg/m2×1–6
without significant short-term side effect; of six cases
reported in children, four went into complete remission
[27–30] and two failed [31], so further data, including long-
term outcomes, are expected. Comparable results have been
published in adults [26].
Preventive measures
The rationale of pre-treatment with CsA for 5–7 days
(trough blood level 250–350 ng/ml) is based on experiment
data. However, the use of a living donor is required for the
planning of pre-treatment and further Tx. Encouraging
results have been obtained from limited series (Fargue, in
preparation). However, living donation should not be
encouraged in the absence of such preventive measures.
Rescue treatments
Angiotensin-converting enzyme (ACE) inhibitors, angioten-
sin 2-receptor blockers and non-steroidal anti-inflammatory
drugs may partially reduce proteinuria without significantly
affecting graft survival.
Many individual approaches have been proposed, espe-
cially for recurrence in a second graft. The risk of recurrence
in such patients is incredibly high, and a strategy different
from that for the first Tx must be suggested. Pre-treatment
using both high doses of CsA and plasmapheresis should be
considered [32]. In the post-Tx course any available option
that was not attempted for the first graft may be proposed,
such as high doses of CsA given intravenously, early
plasmapheresis, cyclophosphamide, and rituximab.
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Haemolytic uraemic syndrome
Most children with haemolytic uraemic syndrome
(HUS) present with a ‘typical’ form, with a 5–10% rate
of ESRD, but 5–10% have an ‘atypical’ course (non-Shiga
toxin-associated HUS), with a high risk of developing
chronic kidney disease (CKD), so that HUS is the primary
diagnosis in 2.5–5% of children with ESRD [5]. Indeed,
more than 50% of patients with non-Shiga toxin-associated
HUS progress to ESRD, and the overall outcome of kidney
Tx is poor (Table 1). However, such atypical HUS is a
group of distinct diseases that may be due to deficient von
Willebrand factor-cleaving protease (ADAMTS 13),
metabolic disorders, or various disorders of complement
regulation [6, 8]. Complement abnormalities include
specific gene mutations in factor H (20–30%), membrane
cofactor protein (MCP, or CD46, 10–15%), factor I
(10–15%), and factors B and C3; no gene mutation is
found in 30–40% of the patients. In addition, approximately
5% of atypical HUSs are due to the presence of anti-
factor H antibodies, leading to a secondary form of factor H
deficiency. Patients with atypical HUS should, therefore,
undergo complement factor determination (C3, factor H,
factor I, factor B, and MCP expression), genotyping
(factor H, factor H-linked genes, factor I, MCP, factor B
and C3) and determination of anti-factor H antibodies
prior to renal Tx so that the risk of graft failure can be
evaluated [6].
Graft failure is often due to endothelial damage, i.e.
vascular thrombosis and disease recurrence. Disease recur-
rence is approximately 0% to 1% in children with typical
HUS and 20% to 80% in atypical HUS (Table 1) [5–7]. The
average time to recurrence is around 1 month but can
be late, after several months as well [8]. Recurrence may be
triggered by viral or bacterial infection and by allograft
rejection; it may also be increased in living donor Tx.
Clinical symptoms of recurrence are often severe. The
overall management and the risk of post-Tx recurrence are
strongly linked to the underlying genotype and associated
pathophysiology of HUS. CsA may cause de novo HUS
in recipients of organ and bone marrow transplants, but it
has no specific effect on outcome of primary HUS
recurrence [33].
Patients with ADAMTS-13 deficiency present either with
neonatal onset HUS or with a recurrent thrombotic throm-
bocytopenic purpura-like course. Few of them have received
transplants, but recurrence is rather frequent and the patient
can benefit from fresh frozen plasma infusion [34].
In MCP mutation, HUS usually presents in children
older than 1 year of age as a recurrent disease of native
kidneys. The transplanted kidney brings a normal MCP, so
that the risk of recurrence after Tx is less than 20% [6, 35].
The option of using a living donor should not be ruled out
when MCP mutation has been proven in the recipient and
excluded in the donor.
In factors H, I or B mutations the clinical presentation is
characterized by early symptoms, i.e. during the first
3 months of life. The recurrence rate in children with
factor H deficiency is 66–76%, and most of them (77–93%)
will lose their graft, so that living donors should be
excluded [5, 6, 35]. Comparable poor results have been
found in patients with factor I mutation: 88% recurrence
rate with 100% graft loss after 1 year [6]. Very few patients
with factor B or C3 mutation but no factor H deficiency
have undergone Tx, but, again, the risk of recurrence seems
to be rather high [5, 6]. The risk of recurrence both in the
autosomal recessive and dominant forms of HUS of
unknown mechanism is not documented in children, but it
is approximately 60% in adults [5].
Factor H and factor I mutations are sometimes regarded
as contraindications to kidney Tx. However, aggressive
treatment with plasmapheresis using fresh frozen plasma
(40–80 ml/kg per session) has provided interesting results
in selected cases [6]. Patients with graft loss despite
plasmapheresis require either long-term dialysis or another
innovative therapeutic option. Human plasma-derived
factor H concentrate has been suggested but is not yet
available, whereas the recent use of anti-C5 monoclonal
antibodies (eculizumab) may allow encouraging results.
Because factor H is synthesized in the liver, combined liver
and kidney Tx (together with pre- and intra-operative
plasmapheresis using fresh frozen plasma and low molec-
ular weight heparin) has been proposed for patients with
severe forms of HUS, with variable results, the more recent
being the more encouraging [6, 36, 37].
For patients with no identified mutation, there are two
options: either wait until new genes are identified, or
proceed with kidney Tx combined with intensive plasma-
therapy [6].
Guidelines are accessible at http://www.espn.ucwm.ac.uk.
Membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis type 1
Membranoproliferative glomerulonephritis type 1 (MPGN-
1) accounts for approximately 2% of the primary
diagnoses of children who receive renal transplants.
The rate of recurrence in children has been reported to
be between 30% and 77%, with graft failure to
recurrence in 17– 50% [10, 38, 39]. Time to recurrence
is 0.5–2 years, and the first sign of recurrence is
proteinuria, which may lead to NS and further graft loss.
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Epstein–Barr virus infection may trigger the recurrence of
glomerular disease [40]. There is no evidence of any
successful treatment, despite anecdotal response to either
plasmapheresis or long-term cyclophosphamide in adults
[10, 41]; however, a combination of both strategies may
be suggested.
Membranoproliferative glomerulonephritis type 2
Membranoproliferative glomerulonephritis type 2 (MPGN-
2) is an uncommon form of complement-dependent
acquired renal disease that often leads to ESRD. It has
been shown in adults that it recurs almost universally, and
up to one-quarter of patients lose their graft from
recurrence [40]. A retrospective analysis of 75 children
found that the 5-year graft survival rate in MPGN-2 was
50.0±7.5%, compared with 74.3±0.6% in patients with
other primary diseases (P<0.001) [42]. Organs from
living related donors have a better 5-year survival rate
than do those from deceased donors (65.9±10.7% and
34.1±9.8%, respectively, P=0.004). Disease recurrence
was present in two-thirds of the 18 patients who
underwent transplant biopsy and was responsible for all
11 graft losses. The risk of recurrence and graft loss is
independent of both pre-Tx presentation and C3 concen-
tration, but it is strongly associated with the presence
of heavy proteinuria, which is the hallmark of clinical
recurrence. The presence of glomerular crescents was
negatively correlated with graft survival, and patients with
histological recurrence experienced higher serum creatinine
concentration and urine protein excretion. In addition, the
risk of graft loss seems to be lower in adults than in children.
There is no available treatment for MPGN-2 recurrence.
Recurrence has not been reported in the very rare
patients with lipodystrophy (Barraquer–Simons disease) -
associated MPGN-2.
Membranous nephropathy
In adults the risk of post-Tx recurrence of membranous
nephropathy reaches 29% after 3 years, without evidence of
specific risk factors; such a recurrence is associated with a
high risk of graft loss, i.e. 38% and 52% after 5 years and
10 years, respectively [43].
Lipoprotein glomerulopathy
ESRD due to lipoprotein glomerulopathy is an excep-
tionally rare condition in children. In adults the risk of
post-Tx recurrence approximates 100% after an average
time interval of 7 months, and the risk of graft loss to
recurrence involves most patients [44]. Neither specific
treatment nor prevention has been advocated, except lipid
lowering and ACE inhibitor therapy. The use of living
donors, therefore, cannot be recommended.
Primary hyperoxaluria type 1
Primary hyperoxaluria type 1 (PH-1) is a recessive
autosomal disease caused by a deficiency of hepatic
peroxisomal alanine:glyoxylate aminotransferase (AGT;
cofactor: pyridoxal phosphate), which catalyses the conver-
sion of glyoxylate to glycine. This leads to overproduction
of oxalate and massive urinary excretion of monohydrated
calcium oxalate. Once CKD has been reached due to
progressive urolithiasis and nephrocalcinosis, insoluble
oxalates accumulate throughout the body and mainly
skeleton and vessels [45]. Since the metabolic defect is in
the liver, isolated kidney Tx cannot correct the primary
metabolic defect but only the damaged target organ. Indeed,
the risk of recurrence in the absence of liver Tx is 90–
100%. A combined liver and kidney Tx is therefore
required for most patients. However, in patients with a
long period of ESRD, the oxalate release from the body
may jeopardize the renal graft, with a picture of recurrence,
despite the metabolic correction associated with synchro-
nous liver Tx. This is the reason why patients with PH-1
should undergo transplantation pre-emptively when their
glomerular filtration rate (GFR) approximates 30–20 ml/
min per 1.73 m2. Some patients who receive a transplant
after a long period of time on dialysis may benefit from a
sequential liver and kidney Tx so that systemic oxalate may
be cleared by dialysis between the liver and kidney Tx
procedures [45].
For any patient, the diagnosis has to be confirmed from
DNA analysis (or from AGT activity measured from a liver
biopsy) before any procedure of organ Tx is considered.
Indeed, some patients may present with hyperoxaluria
without AGT deficiency, leading to a diagnosis of either
PH-2 (glyoxylate reductase/hydroxypyruvate reductase
deficiency) or non-PH-1 non-PH-2 where Tx strategy has
not been clearly delineated. DNA analysis for patients with
PH-1 is of pivotal interest, since (1) a small number of
patients with the Gly170Arg AGXT mutation (Western
Europe) may present with evidence of pyridoxine respon-
siveness, sometimes allowing isolated kidney Tx with
lifelong pyridoxine intake and (2) patients with the
Ile244Thr AGXT mutation (North Africa, Spain) do not
respond to pyridoxine and, therefore, require combined
liver and kidney Tx; (3) experience of other mutations is
limited and leads to the recommendation of combined
liver and kidney Tx [45–47]. However, correlation with
clinical phenotype and treatment response is complicated
by the involvement of other genetic (e.g. modifier genes)
and non-genetic (e.g. environmental) factors that affect
disease severity [48].
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Recurrence with a low risk of graft loss
IgA nephropathy
Berger disease
Up to 25% of patients with IgA nephropathy develop
ESRD, and 35–60% will experience a histological recur-
rence of the disease [11, 49, 50]. These patients present
with persistent microscopic haematuria and proteinuria, and
renal transplant biopsy often shows mesangioproliferative
glomerulonephritis, and not only silent recurrent mesangial
IgA deposits from protocol biopsy. The risk of recurrence is
not correlated with donor status, recipient age, race, gender,
or immunosuppression [51]. After an average follow-up
period of 61 months, 18 of 63 adult patients experienced
recurrence, which led to graft loss in six [50]. Younger
adult patients seem to be more prone to the risk of
recurrence, but recurrence rate in children has not been
documented enough; however, the percentage of graft loss
to recurrence is approximately 7% [11, 52]. Proteinuria is
associated with progressive loss of function in all patients
with recurrent IgA nephropathy.
Henoch–Schönlein purpura
The recurrence rate of Henoch–Schönlein purpura (HSP)
after transplantation in children is common from protocol
biopsies, but most data come from series of adults. There is
an increased risk of disease recurrence in the aggressive
progression to ESRD and when a living related donor has
been used, but there is no influence from the type of post-
transplantation immunosuppression [53, 54].
Systemic lupus erythematosus
Results of kidney Tx in systemic lupus erythematosus
(SLE) are rather good, since there is no significant risk of
clinical recurrence [9, 55]. Some series report a 30%
histological rejection rate and a greater risk of thrombotic
complications (particularly in patients with antiphospholi-
pid antibody syndrome) [9, 56]. Such an overall favourable
outcome is probably due to the adequate immunosuppres-
sive effect of anti-rejection regimens that keeps SLE in
remission. In adults the overall graft survival rate is 87%
after 1 year and 60% after 5 years [56]. In children SLE is
responsible for approximately 3% of ESRD leading to
kidney Tx in North America; allograft survival is not
different from that in non-lupus renal diseases, but patient
survival is worse, i.e. 1.8 relative risk of death in
multivariable analysis [57].
Anti-neutrophilic cytoplasmic antibody-associated
small vessels vasculitides
Recurrence of idiopathic, pauci-immune, anti-neutrophilic,
cytoplasmic antibody (ANCA)-associated (usually antimye-
loperoxidase) necrotizing glomerulonephritis after renal Tx is
rare, thanks to the adequacy of immunosuppression, so that
the overall results are good. A combination of cyclophospha-
mide, corticosteroids and, sometimes, plasmapheresis has
been successful in case reports [58, 59]. Interestingly,
sirolimus may lower ANCA titres before kidney Tx and,
therefore, may be considered in the post-Tx immunosup-
pression regime [60].
Wegener granulomatosis is a very rare cause of graft loss
in children. The experience of renal Tx in adults shows that
the risk of graft loss to recurrence ranges between 0% and
6%, with a comparable outcome to that in other non-
diabetic primary diseases [55, 61].
Methylmalonic acidaemia
Kidney Tx has provided acceptable results for the small
number of patients with ESRD due to methylmalonic
acidaemia (MMA). However, systemic production of MMA
persists after kidney Tx, despite dietary protein restriction, so
that plasma MMA remains at a lower range than before Tx
according to post-Tx GFR but still many times greater than
that in healthy subjects [62]. The progression of the disease
after Tx therefore depends on both compliance and probably
other individual metabolic parameters such as genotype, so
that combined liver and kidney Tx has been proposed for
selected patients, with variable results.
Recurrence with a long-term risk of graft loss
Insulin-dependent diabetes mellitus, sickle cell disease,
endemic/Balkan nephropathy
Some renal diseases may lead to ESRD during late
childhood or early adulthood, with a high risk of recurrence
for as long as the primary disease causing the disorder is
present. Such a recurrence is a delayed phenomenon and
always occurs in adulthood, many years after the primary
renal Tx. This has been shown for inherited diseases (e.g.
insulin-dependent diabetes mellitus, sickle cell disease) as
well as for some acquired diseases (e.g. endemic/Balkan
nephropathy) when the causing agent is still present [63].
Sarcoidosis
Renal involvement leading to CKD and further ESRD is
rare, mainly in children. Very few cases of sarcoidosis
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recurrence in renal allograft recipients have been published,
all of them affecting adults [64].
Adenine phosphoribosyl-transferase deficiency
Very few patients with adenine phosphoribosyl-transferase
deficiency and 2,8-dihydroxyadenine tubulointerstitial
lesions present with ESRD of ‘unknown origin’ and no
history of nephrolithiasis. Some of them, therefore, undergo
transplantation in adulthood, with a risk of post-Tx stone
recurrence [65]. Once the diagnosis has finally been
established, a treatment based on allopurinol, purine-
restricted diet and hydration is effective.
Recurrence/occurrence of specific features
of the primary disease
A large number of hereditary renal diseasesmay lead to ESRD
and kidney Tx. In general, due to the molecular pathophys-
iology of such diseases, there is no risk of recurrence, except
for some patients in whom graft function may be jeopardized
by the occurrence of specific auto-antibodies.
Genetic forms of NS
Proteinuria
Owing to constitutional glomerular abnormalities, there
is no risk of recurrence of the primary disease in inherited
NS (Table 2) after Tx of a ‘new kidney’ [14, 17]. This has
been shown for most patients with dominant FSGS and for
patients with syndromic NS (WT1-associated NS, Schimke
disease, Pierson syndrome, Galloway syndrome, Charcot–
Marie–Tooth disease).
However, some patients with genetic NS present with
proteinuria after Tx in the absence of specific features of
the primary disease; this may be due to antibody-mediated
glomerular injury leading to increased permeability and
proteinuria. Such a complication has been found in patients
with the Finnish type NS (anti-nephrin antibodies in
Maj/Maj homozygous patients) and recessive FSGS (anti-
podocin antibodies).
Cancer
Patients with WT1 mutations have an increased intrinsic
risk of cancer in residual tissues, so that target organs must
be removed prior to Tx, i.e. bilateral nephrectomy in
Denys–Drash syndrome and bilateral gonadectomy
in Frasier syndrome. In the case of tumours, prior to Tx, a
one to two-year interval between the last specific treatment
course and Tx is recommended [66].
Other organ involvements
Very few patients present with Schimke immuno-
osseous dysplasia, including FSGS-related CKD, combined
immune deficiency, spondylo-epiphyseal dysplasia,
vascular endothelial disease and specific morphological
abnormalities. Most of these patients die during the first
years of life because of severe opportunistic infections, but
some of them survive further ESRD. In such recipients,
there is no increased risk of post-Tx recurrent proteinuria or
NS, but kidney Tx is still a life-threatening option because
of additional immunosuppression. Interestingly, some
patients have been successfully treated with kidney Tx
following prior bone marrow Tx [67].
Anti-glomerular basement membrane antibodies-associated
glomerulonephritis
Alport syndrome
Anti-glomerular basement membrane GBM) antibodies
occasionally occur in Alport patients after renal allograft
Tx. The association of high titres anti-GBM antibodies and
vascular rejection may be important so that anti-GBM
antibodies should be sought in the presence of vascular
rejection in Alport patients [68].
Goodpasture syndrome
Goodpasture syndrome is a rare cause of ESRD in
children. Graft loss to recurrence has been estimated to
be approximately 14% in adults, but the recurrence of anti-
GBM nephritis has rarely been documented, either in the
native kidneys or after renal Tx [55]. However, some
patients with recurrent fulminant anti-GBM nephritis have
been reported after Tx with the reappearance of circulating
anti-GBM antibodies at the time of recurrence [69].
Graft involvement as a consequence of lower urinary tract
abnormality
A normal bladder acts as a low pressure, good volume,
urinary reservoir that is continent, sterile and empties freely
and completely. When such an environment is not
achieved, infection and renal impairment may occur and
recur after kidney Tx. Abnormal bladders must, therefore,
be assessed urodynamically prior to Tx. A multidisciplinary
team approach is required for such patients.
In most series of adults, as well as in children, patients with
abnormal bladders, mainly posterior urethral valves, or
urinary diversion experience worse graft function than those
do with primary renal diseases, but graft survival is
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comparable [70]. Graft dysfunction may sometimes be due
to both repeated urinary tract infection and abnormal urinary
pressure, so limited surgical interventions prior to Tx and
post-Tx antibiotic prophylaxis are recommended [71].
Human immunodeficiency virus infection
Human immunodeficiency virus (HIV) nephropathy may
lead to ESRD and involves 7–12% of African–American
HIV-infected male patients [72]. Thanks to current highly
active anti-retroviral therapy, HIV patients are now exposed
to the risk of suffering from ESRD, and renal Tx may be
proposed for selected paediatric recipients [73]. Indeed,
there are now several reports of favourable outcome after
Tx, since immunosuppression may have beneficial effects
for such patients through moderation of immune activation
or reduction of HIV reservoirs. Specific immunosuppres-
sants drugs also have antiviral properties or interact
positively with certain antiviral agents [72].
Thrombosis
Patients with antiphospholipid antibody syndrome are at
high risk of post-Tx renal thrombosis that could be
prevented by anticoagulation therapy [74].
Inherited thrombophilia may lead to venous thrombosis,
microvascular occlusion or acute rejection, with major
consequences for graft survival. Some specific genotypes,
mainly prothrombin mutations, are associated with such
causes of graft failure, so pre-Tx screening for thrombo-
philia is recommended and should lead to pre- and post-Tx
anticoagulation strategies [75].
Different from recurrence
De novo diseases
Focal segmental glomerulosclerosis
The occurrence of late de novo FSGS after Tx may be
due to chronic transplant nephropathy, anticalcineurin
toxicity, etc.
Thrombotic microangiopathy
Thrombotic microangiopathy (TMA) is characterized by
aggregation of platelets in the renal and/or systemic circula-
tion, thrombocytopenia and intravascular haemolysis. Inde-
pendent of a recurrence of the original disease, it has been
reported after Tx in 0.8% of patients in the United States of
America, mainly during the first 3 months after Tx. Risk
factors for the whole Tx population include younger recipient
age, older donor age, female recipient, initial use of sirolimus
and calcineurin inhibitors, acute rejection and viral infection
[76, 77]. Of adults treated with calcineurin inhibitors, 3%
develop de novo TMA; 62% present with systemic TMA
and 38% with TMA limited to the graft; the prognosis is
better in patients with localized forms who show a better
response to reduction, conversion or temporary discontinu-
ation of calcineurin-inhibitor treatment.
IgA nephropathy
De novo mesangial deposition of IgA in renal allografts
is not a rare feature and is usually clinically benign.
However, some case reports have shown that it can present
with crescentic lesions and lead to deterioration of graft
function and, sometimes, graft loss [78].
Diabetic nephropathy
De novo diabetic nephropathy is a rare event after Tx but
may follow a decade-long course and further lead to graft
loss [63].
Isolated specific deposits
Cystinosis
Renal transplantation has significantly prolonged the
survival of patients with infantile cystinosis, so that
the long-term outcome of the disease has changed during
the past decades. Indeed, cystine continues to accumulate
unabated in most organs and will lead to late systemic
complications, such as visual impairment, hypothyroidism,
central nervous system involvement, distal myopathy, and
endocrine pancreatic insufficiency, which may trigger post-
Tx diabetes mellitus at the time of glucocorticoid-based
immunosuppression [79]. Most risks may be postponed by
the daily use of cysteamine as soon as the diagnosis has
been made, as well as following kidney Tx and later on.
There is no risk of recurrence of the primary disease in
the graft, but protocol biopsies have shown that cystine
crystals may be deposited within the interstitial tissue
without any clinical or biological manifestation.
Fabry disease
Fabry-related ESRD occurs in adulthood, but the
challenge of kidney Tx in these patients must be known
as early as when the diagnosis has been confirmed, i.e. in
children and adolescents. Transplants in adults have an
excellent graft survival rate, which is statistically similar to
the rates of graft survival in patients without Fabry disease
[80]. Surprisingly, from the North American experience in
adults, patient survival rate and the risk of cardiovascular
death in untreated patients with Fabry disease is compara-
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ble to those of other renal Tx recipients [80]. Such results
may be due to the selection of patients, and there is now a
rationale to treat any kidney transplant patient with enzyme
replacement therapy, as renal Tx does not correct the
underlying metabolic defect in other organs [81].
Infection
Independent of primary disease, some patients lose their
graft from polyoma BK virus-acquired nephropathy. Re-
transplantation may be successful in the absence of graft
nephrectomy, provided that findings for BK virus DNA
were negative, both in the blood and in the urine (or kidney
material) at the time of re-transplantation [82].
Conclusions
Disease recurrence is currently one of the most challeng-
ing issue in paediatric kidney transplantation. However,
graft loss and patient morbidity may benefit from a better
approach to disease pathophysiology, better risk evalua-
tion and improved individualized treatment strategies.
DNA analysis should be performed as far as available,
but adequate material should be stored for further inves-
tigations. Specific strategies should be added to kidney
transplantation if necessary, such as donor selection,
associated liver transplantation, plasmapheresis, and
specific immunosuppression protocols. Therefore, very
few patients may be excluded from kidney transplantation
only because of a major risk of disease recurrence and
repeated graft loss. In the near future, the issue of disease
recurrence after kidney transplantation may benefit from
new approaches to alternatives to organ transplantation,
such as recombinant proteins, specific monoclonal
antibodies, cell therapy, gene therapy, and chaperone
molecules. The use of international registries and data-
bases is of major concern in any project including
interventional study.
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